Product category:
Clinical chemistry analysis
News Release from: Perkin Elmer LAS (UK) | Subject: Delfia
Edited by the Laboratorytalk Editorial
Team on 19 April 2002
Probing the source of diabetes
Newly developed gene probes increase efficiency and speed of research in studies of type 1 (juvenile) diabetes, detecting the presence of alleles by hybridisation reaction
PerkinElmer Life Sciences has announced the introduction of a full set of gene probes for use in genetic typing of type 1 diabetes Based on its Delfia technology, these probes provide an effective method for significantly increasing daily sample throughput, enabling quicker, more effective research
This article was originally published on Laboratorytalk on 17 Dec 2002 at 8.00am (UK)
Related stories
Simpler tests for juvenile diabetes
New, highly sensitive assays for research into Type 1 or 'juvenile' diabetes should speed discovery of possible cures
Assay determines predisposition to celiac disease
Sensitive, easy-to-perform test on hybridisation assay ascertains an individual's susceptibility to celiac disease and provides improved tool for growing area of research
They are capable of handling large sample volume throughput, and are less technically demanding than traditional solutions.
Type 1 or juvenile diabetes results from an autoimmune disorder in which the immune system mistakenly attacks the body's insulin-producing pancreatic cells, reducing and ultimately stopping all insulin production.
The cost of care for a type 1 diabetes patient is a burden to both the patient and society.
Although there is still no cure for juvenile diabetes, early detection can prevent or at least reduce rates of long-term complications, both improving the quality of life and reducing the costs that result from repeated hospitalisations.
The probes specific for HLA-DQB1, -DQA1 and -DRB1 alleles are currently used exclusively for research to discover the genes involved in conferring a genetic risk of or protection from developing type 1 diabetes.
Once the DNA in a blood sample is amplified, the presence of particular alleles relating to type 1 diabetes can be determined by a hybridisation reaction using allele-specific, short oligonucleotides labelled with lanthanide chelates.
"PerkinElmer Life Sciences's development of high-performance probes specifically for diabetes-related genes represents a significant industry advancement," said Ann-Christine Sundell, vice president and general manager, genetic screening, PerkinElmer Life Sciences.
"We are already close to being able to predict this disease, and the possession of information on risk and protective alleles will be extremely valuable to the vast body of researchers who are working toward finding a cure." PerkinElmer Life Sciences is in the advanced stages of developing a suite of solutions for clinical screening for type 1 diabetes ranging from HLA-typing probes and autoantibody kits to sophisticated software for data management and risk analysis.
• Perkin Elmer LAS (UK): contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
